Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are difficult to treat, and account for up to 30% of prostate cancer-related deaths every year. While existing therapies for prostate cancer such as androgen deprivation therapy (ADT), destroy the bulk of the ARpositive cells within the tumor, eradicating this population eventually leads to castration-resistance, owing to the continued survival of AR -/lo stem-like cells. In this study, we identified a critical nexus between p38MAPK signaling, and the transcription factor Forkhead Box Protein C2 (FOXC2) known to promote cancer stem-cells and metastasis. We demonstrate that prostate cancer cells that are insensitive to ADT, as well as high-grade/NE prostate tumors, are characterized by elevated FOXC2, and that targeting FOXC2 using a well-tolerated p38 inhibitor restores epithelial attributes and ADT-sensitivity, and reduces the shedding of circulating tumor cells in vivo with significant shrinkage in the tumor mass. This study thus specifies a tangible mechanism to target the AR -/lo population of prostate cancer cells with stem-cell properties.
INTRODUCTION
Prostate cancer (PCa) progression to metastatic disease accounts for 410% of all cancer-related deaths in men. Androgen deprivation therapy (ADT) remains the principal treatment for PCa. While this results in initial tumor regression, the majority of these patients become noncompliant to this line of treatment, owing to the emergence of androgen-independent mechanisms promoting tumor cell growth. Moreover, although most initially diagnosed PCas are acinar adenocarcinomas that display elevated expression of the androgen receptor (AR) and its target gene prostate-specific antigen (PSA), a substantial proportion of patients present atypical clinical features, and are characterized by the blatant absence of AR and PSA, but instead display immunoreactivity to neuroendocrine (NE) differentiation markers such as chromogranin A, synaptophysin, CD56 and neuron-specific enolase. While these AR/PSA-negative NE PCas (NEPC) (or small-cell prostate carcinomas) are rare at the time of initial diagnosis, they however, account for 10-30% of advanced recurrent castration-resistant PCas (CRPC, high-grade Gleason) following ADT. 1 These variant 'AR-negative PCa' or NEPCs are extremely aggressive, androgen-independent, metastatic and therapy resistant, with their 5-year overall survival being dismal at 12.6%, which categorizes them as the most deadly subset of all PCa. 2 Currently, there are no targeted therapies available for this class of patients; their AR-negativity presents a major therapeutic challenge.
It has long been recognized that androgens and AR exhibit key tumor suppressive effects in the prostate. Genetic ablation of AR in prostate epithelial cells has actually been demonstrated to promote the development of invasive prostate tumors, 3 while targeting AR with siRNA has been shown to promote metastasis through enhanced macrophage recruitment via STAT3 activation. 4 Moreover, AR expression is significantly reduced in metastatic hormone-resistant PCa, 5 while AR signaling was found to be severely attenuated in some advanced PCa. 6 Collectively, this argues that restoration of AR and AR signaling could indeed have beneficial effects for the select class of PCa patients (such as those diagnosed with NEPC/small-cell prostate carcinomas, or even advanced adenocarcinomas displaying NE differentiation following ADT) that feature loss of AR or its downstream molecular targets.
Emerging evidence implicates the existence of a subpopulation of androgen-insensitive stem-like cells in prostate tumors (PCaSCs) that may potentially aid in tumor recurrence, metastatic progression and therapy-resistance. [7] [8] [9] [10] However, the origin of these cells and the molecular factors governing their stem-cell behavior are still poorly understood, although there have been suggestions that PCaSCs may be NE in nature (and hence AR/PSA -/lo ). 11 In a recent report aimed at characterizing the cancer stem-cell (CSC) pool from PCa explants, drug-resistant sphere cultures were found to be particularly enriched for cytokeratin 18, suggesting their epithelial origin. 7 Further, elevated expression of Zeb1, an epithelial-mesenchymal-transition (EMT) transcription factor associated with stem-cell properties, in androgen-independent PCa cells as well as in prostate tumors of castrated PTEN conditional knockout mice advocates that PCaSCs are possibly products of EMT. 12 EMT refers to a complex cellular reprogramming process that facilitates the conversion of differentiated epithelial cells into loosely organized, highly migratory and invasive mesenchymal cells. Although there are multiple suggestions that deviant activation of EMT pathways may facilitate the development of PCa, and possibly, aid in its progression to the advanced therapyresistant state, [12] [13] [14] the precise molecular mechanisms that dictate the EMT/CSC-mediated shift to altered AR signaling as well as to androgen-independence, and the source of stem-cells in PCa progression, remain largely undefined.
Employing a PSA promoter-driven lentiviral EGFP reporter system, we previously demonstrated that in both primary PCa tissues, and in established PCa cell lines, the PSA -/lo cells represent a functionally unique subpopulation that is selectively enriched for cells characteristic of castration-resistant PCaSC. 15 This undifferentiated pool of cells expresses classical PCaSC markers (ALDH, CD44, α2β1-integrin), and undergoes asymmetric cell division to generate the PSA + /differentiated counterpart of prostate epithelial cells. Further, these cells are endowed with elevated clonogenic potential and tumor-propagating capacity, thereby highlighting the potential clinical benefit of effectively targeting this subpopulation of PCa cells. In a distinct set of studies, we previously identified the central EMT regulator Forkhead Box Protein C2 (FOXC2) as an independent factor necessary and sufficient to bestow carcinoma cells with CSC features, as well as with migratory and invasive capacities required for tumor progression in vivo. 16, 17 In this manuscript, we demonstrate a direct link between PSA -/lo PCa cells, the EMT/CSC archetype and regulated AR expression, and establish a vital role for FOXC2 in the induction and maintenance of ADT-resistant PCaSC attributes. Further, we describe the use of a novel approach to target FOXC2 expression/function as an effective method of inhibiting the generation/ function of tumor-promoting PSA -/lo AR -/lo stem-like cells, while simultaneously restoring epithelial attributes in these cells, hence resensitizing them to ADT.
RESULTS

PSA -/lo PCa stem-like cells exhibit augmented EMT properties
We have recently shown that the PSA -/lo subpopulation of cells from primary human prostate tumors, as well as from various PCa cell lines, represent self-renewing, tumor-propagating cells resembling PCaSC. 15 We have also previously demonstrated that in breast carcinoma, EMT constitutes a major source for the generation of such tumor-propagating stem-like cells. 17 To investigate the relationship between EMT and PSA, we isolated PSA + and PSA -/lo sub-fractions, from the androgen-responsive LNCaP cell line expressing the PSA promoter driving green fluorescent protein (GFP) expression, as described previously, 15 and analyzed the expression of well-characterized EMT markers. In comparison to the PSA + (GFP + ) fraction, the PSA -/lo (GFP -/lo ) cells clearly appeared more mesenchymal (Figure 1a ). Quantitative reverse transcription-PCR (qRT-PCR; Figure 1b ) and western blot ( Figure 1c ) analyses revealed that the stem-like PSA -/lo cells exhibited markedly diminished expression of prostate epithelial differentiation markers AR and PSA, as expected, with simultaneously elevated expression of known stem-cell markers, Bmi1 and Sox2 18 as well as NE differentiation markers 2 (Figure 1b ). In addition, PSA -/lo cells also exhibited significantly reduced expression of the epithelial marker E-cadherin, and increased expression of mesenchymal markers and the central EMT regulator, FOXC2 (Figures 1b and c). Immunofluorescent staining further confirmed the loss of expression and plasma membrane localization of E-cadherin, with concomitant increase in expression of CSC markers Zeb1 19, 20 and FOXC2 in PSA -/lo cells (Figure 1d ). These results suggest that even in the androgen-dependent LNCaP cell line, the PSA -/low cells resembling stem-like cells, display the EMT phenotype as well as NE-like features.
Androgen-independent metastatic PCa cell lines possess increased EMT/stem-cell features While LNCaP cells are androgen-dependent and poorly invasive, the androgen-independent DU145 and PC3 cells are far more invasive and harbor significantly higher metastatic potential. 21 We observed that LNCaP cells predominantly exhibited epithelial features including expression of AR/PSA and E-cadherin (Figures 1e and f ). DU145 and PC3 cells, on the other hand, exhibited significantly increased expression of EMT-associated mesenchymal markers, as well as NE differentiation markers, with simultaneous loss of E-cadherin levels (Figures 1e and f) . Interestingly, expression of FOXC2 was restricted to the androgenindependent metastatic cell lines DU145 and PC3, and almost undetectable in the weakly invasive non-metastatic LNCaP cells ( Figure 1f ).
Since FOXC2 is known to empower tumor cells with stem-cell attributes in breast carcinoma, 17 we tested these PCa cell lines for stem-cell properties including their ability to form prostospheres, and expression of stem-cell-related cell-surface markers CD44 and CD24. 22 In correlation with their reduced sphere-forming capacity in non-adherent cultures, the poorly invasive LNCaP cells harbored o 1% CD44 hi /CD24 lo stem-cell-enriched fraction (Figures 1g and h) . In contrast, more than 85% of the metastatic DU145 cells were CD44 hi /CD24 lo (Figures 1g and h) , consistent with increased expression of other known stem-cell markers, Bmi1 and Sox2 (Figure 1e ). We also observed that the two PCa cell lines expressing high levels of endogenous FOXC2-DU145 and PC3-formed significantly higher number of tumorspheres ( Figure 1i ), indicating higher stem-like potential compared with LNCaP cells, which have very low FOXC2 expression. Interestingly, the PCa cells that have higher metastatic potential and augmented stem-cell properties consistently lack AR/PSA expression (Figures 1e and f).
FOXC2 expression heralds the androgen-independent state associated with loss of AR/PSA expression, poor Gleason scoring and recurrent PCa We previously discovered that FOXC2 is not expressed in differentiated breast cancer cells but is markedly upregulated following EMT, and is enriched in CSC fractions. 23 We therefore examined whether induction of EMT in PCa cells would similarly result in upregulation of FOXC2. Indeed, we found that over- To further investigate the physiological significance of FOXC2 in prostate tumor progression, we analyzed the GDS4109 GEO database that contains non-recurrent and recurrent PCa samples. Notably, FOXC2 expression was significantly higher in the recurrent samples ( Figure 2g ). Moreover, we found a direct correlation between markedly increased FOXC2 levels and high Gleason grading, in two independent publicly available data sets (GSE17356 ( Figure 2h ) and TCGA (Figure 2i) ). To confirm the relevance of these observations, we performed immunohistochemistry (IHC) analyses for FOXC2 protein in patient-derived primary prostate tissue samples ranging from benign prostatic hyperplasia, to prostatic intraepithelial neoplasia, to advanced grade Gleason 7. Interestingly, we discovered a correlation between high expression of FOXC2 and high Gleason grading associated poor clinical outcome (Figure 2j , Supplementary Figure S1 ), reaffirming our earlier observations. Further, in aggressive small-cell carcinoma of the human prostate characterized by lack of AR, we observed significantly elevated expression shZeb1
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mRNA expression relative to vector control cells Figure S2) . Similarly, in patient-derived xenograft models of human prostate tumors exemplified by castration-resistance, NE features and loss of AR, 24, 25 we consistently observed increased FOXC2 expression (Supplementary Figure S3 ). Together, these data suggest that expression of FOXC2 in PCa cells segregates with the androgen-independent state that is associated with increased stemness.
Enforced expression of FOXC2 induces the EMT/CSC phenotype and increased drug-resistance Since FOXC2 is induced downstream of several different EMT inducers, and is by itself capable of potentiating the effects of multiple independent EMT signals, 17, 26 (Figure 3h ). DU145 cells are androgen-independent and insensitive to the AR inhibitor Enzalutamide, even at 10 μM. 27 However, suppression of FOXC2 in these cells rendered them more sensitive to Enzalutamide even at 100 nM, as determined by the MTS cell survival assay ( Figure 3n ). Emergence of Docetaxel-resistance in PCa remains an important therapeutic hurdle, and DU145 cells represent a good model system to study mechanisms altering Docetaxel-resistance. 28 Interestingly, loss of FOXC2 expression rendered DU145 cells more susceptible to 100 nM Docetaxel treatment ( Figure 3o ). Together, these results suggest that FOXC2 expression is necessary and sufficient for the induction of PCaSC attributes associated with loss of AR/PSA expression and emergence of androgen-independence and chemo-resistance.
FOXC2 regulates AR via Zeb1, a known transcriptional repressor It is notable that although FOXC2 functions as a transcriptional activator in most cell types studied, its expression in PCa cells, however, causes a drastic loss of AR/PSA levels. In this context, it is pertinent to reveal parallel studies from our laboratory performed in breast cancer cells, which demonstrate that FOXC2 exerts its repressive effects indirectly through Zeb1, a known transcriptional repressor (Werden et al., under review). We therefore investigated if similar links are operative in PCa cells. In LNCaP cells overexpressing FOXC2, we observed that enforced loss of Zeb1 drastically obliterates the AR-repressive effect of FOXC2 (Figure 4a ), as well as their stem-cell properties (Figure 4b ), and resistance to Enzalutamide (Figure 4c ). Further, overexpression of Zeb1 in DU145 cells lacking FOXC2 expression was sufficient to cause a significant downregulation in AR levels (Figure 4d ), with restoration of sphere-forming capacity (Figure 4e ) and resistance to Enzalutamide (Figure 4f ). These data suggest that FOXC2dictated PCaSC attributes associated with loss of AR expression and emergence of ADT-resistance are mediated by Zeb1.
Activation of p38MAPK signaling correlates with FOXC2-associated EMT/stem-cell features p38 mitogen-activated protein kinases (MAPK) are known to play key roles in cellular proliferation, differentiation, apoptosis, invasion and migration-attributes that are all significantly altered during the course of cancer progression. 29 In a parallel study using breast cancer cells, we found that FOXC2 not only possesses functional phosphorylation sites for p38MAPK14, but that both FOXC2 and the active form of p38 (phospho-p38) are consistently high in cells that have undergone EMT, as well as in CSC-enriched cell populations (Werden et al., under review). In fact, we observed that PCa cells with inherent mesenchymal and stem-cell properties (DU145/PC3 relative to LNCaP or PSA hi relative to PSA -/lo ) exhibit significantly increased p-p38 and its direct target, Activating Transcription Factor-2 (pATF2) (Figures 5a and d) , which strongly correlates with FOXC2 expression (Figures 1b, f and 5c, d) .
We further tested this correlation between FOXC2 expression and p38 activation in yet another model of prostate EMT induction, using Transforming Growth Factor-β1 (TGFβ1). TGFβ1 is a well-characterized activator of p38 signaling, and has been shown to induce EMT in a variety of epithelial cell types including the prostate. 29, 30 Treatment of LNCaP cells with TGFβ1 resulted in moderate induction of EMT, FOXC2 expression, as well as concurrent activation of p38 signaling (Figure 5e ), and increased stem-cell function (Figure 5f ). On the contrary, suppression of TGFβ1 signaling in DU145 cells using LY364947, resulted in a concomitant loss of FOXC2 expression and p38 signaling (Figure 5e ), with markedly reduced tumorsphere-forming capacity (Figure 5f ). Together, all the above data suggest that targeting FOXC2, by interfering with p38 signaling, may provide a therapeutic solution to preventing CSC generation/function in androgen-insensitive PCa cells.
Interestingly, we discovered a potential p38 phosphorylation site harbored within a consensus sequence on human FOXC2 protein (Figure 5g ). We next investigated the functional relevance of this putative site in facilitating FOXC2-mediated stem-cell functions in PCa cells. While expression of the S367E-FOXC2 mutant, which mimics constitutive p38 phosphorylation, enhanced sphere formation and Zeb1 expression associated with loss of AR, the S367A-FOXC2 mutant, which represents the non-p38-phophorylatable form of FOXC2, resulted in a loss of stem-cell function and Zeb1 expression, with concomitant restoration in AR expression (Figures 5h and i) . These results suggest that FOXC2 may be a direct target of p38 in PCa cells, and further that the S367 site plays a key role in mediating FOXC2 functions in these cells.
Suppression of p38 signaling results in reversal of EMT and significant decrease in stem-cell properties Treatment of DU145 cells with SB203580, a specific chemical inhibitor of p38 signaling, for 7 days resulted in their acquisition of an epithelial phenotype (Figure 6a ), with significant reduction in migratory potential (Figures 6b and c) . This was accompanied by a dramatic loss of FOXC2 expression and consequent EMT/CSC features (Figures 6d and e ), including significant reduction in the CD44 hi /CD24 lo fraction (Figures 6f and g) , expression of Bmi1 and Sox2 (Figure 6d ), and tumorsphere formation (Figure 6h ). Figure S4) . Interestingly, such restoration of AR/PSA expression with simultaneous loss of FOXC2 brought about by SB203580 pre-treatment, significantly resensitized these cells to subsequent co-treatment with SB203580 and either Enzalutamide (Figure 6j ) or Docetaxel (Figure 6k ), suggesting that a combinatorial approach might be effective in targeting highly invasive PCa cells that are resistant to ADT and standard chemotherapy. 
Combinatorial suppression of p38 signaling with Enzalutamide treatment significantly reduces tumor size
To investigate the effect of inhibition of FOXC2-dependent EMT/CSC attributes on tumor formation in vivo, we s.c. injected NOD/SCID mice with DU145 cells and began treatment in vivo, after formation of palpable tumors. The treatment plan/schedule is depicted in Figure 7a . While there was no appreciable change in tumor size in mice treated singly with either SB203580 or Enzalutamide compared with the vehicle-treated group, mice treated with a combination of SB203580 and Enzalutamide showed a significant decrease in tumor volume and weight (Figures 7b and e, Supplementary Figure S5 ). This suggested that although parental DU145 cells are Enzalutamide-resistant to begin with, co-treatment of cells with the p38 inhibitor and Enzalutamide, once again confers susceptibility to ADT. In direct corroboration of our in vitro results (Figure 6) , such a combinatorial (Figures 7f and g) .
EMT has long been recognized to provide a 'passport' to tumor cells allowing their invasion of tissue boundaries and entry into circulation. These 'altered' circulating tumor cells (CTC) then go on to sow the seeds for distant metastasis. In support of an important role for FOXC2-mediated EMT/CSC properties facilitating prostate tumor cell shedding into circulation, we indeed observed that combinatorial treatment markedly reduced the number of CTCs in mice, quantified as red fluorescent protein (RFP)-positive CTC colonies isolated from blood (Figure 7h ).
DISCUSSION
Multiple recent efforts have collectively proposed that androgen depletion (the mainstay treatment for PCa) results in the induction of tumor-promoting EMT, suggesting that patients undergoing ADT might benefit from concurrent treatment with an inhibitor of EMT signaling. 13, 31, 32 However, effective administration of anti-EMT therapies constitutes a substantial challenge. Among the most attractive targets are EMT transcription factors (such as Snail, Twist or Zeb1). 12, 33, 34 Unfortunately, they are not readily 'targetable' therapeutically. Furthermore, contemporary treatment regimens, besides facilitating EMT in PCa cells, also promote adaptive tumor plasticity via NE trans-differentiation, a process that is associated with resistance to therapy, visceral metastasis and aggressive disease. 35 We therefore sought to develop an alternative method that relies on the proclivity of cancer cells to drastically alter their cellular signaling pathways to fuel growth and survival; most importantly a tangible method designed to eliminate the source/generation of PCa stem-like cells, the tumor cell subpopulation that critically determines tumor initiation, recurrence, castration-resistance and metastatic progression.
Our current studies using patient-derived prostate tissue samples as well as human PCa cell lines with differing properties of androgen-dependence and drug-resistance, establish the strong correlation between FOXC2 (a known EMT transcription factor) 17 expression and loss of AR function associated with castration-resistant prostate tumor progression. We therefore queried the possibility of using signaling inhibitors impacting FOXC2 expression/function to thwart CSC features in metastatic androgen-insensitive PCa cells. One such 'targetable' regulator of FOXC2 we have identified is the p38MAPK, a family of key serine/ threonine kinases controlling cellular responses to cytokines and stress. Interestingly, the p38 signaling cascade has been previously implicated in facilitating multiple aspects of PCa progression. [36] [37] [38] [39] [40] [41] p38MAPK can be effectively inhibited by small molecule therapeutics, which have already been shown to exhibit favorable activity in phase II clinical trials, for other medical conditions such as chronic obstructive pulmonary disease, cardiovascular disease and rheumatoid arthritis. [42] [43] [44] In this report, we propose a novel extension of its application to androgen-insensitive, drug-resistant PCas harboring stem-like attributes.
Intriguingly, Khandrika et al. 40 have reported that activation of p38 signaling in PCa cells may represent an adaptive response to hypoxic stress. Our studies done under normoxic conditions suggest that PCa cells activate p38 signaling on induction of EMT and consequent acquisition of stem-cell features, probably reflecting the early stages of transition to androgen-independence, wherein hypoxic stress is not yet pronounced. However, we predict that intervention by blockade of such a key signaling pathway leading to FOXC2-mediated stabilization of CSC attributes, is bound to be beneficial even at later stages of PCa progression, especially since invasive CTCs with stem-cell features have been detected in men with advanced metastatic CRPC. 9 It is important to note that suppression of FOXC2 in invasive AR -/lo DU145 PCa cells was sufficient to restore AR expression and function, as judged by upregulation of its downstream target, PSA (Figures 3, 6 and 7) . Restoration of AR/PSA expression and the associated epithelial state with loss of stem-cell functions (either using SB203580, or directly, through FOXC2 suppression) rendered these androgen-independent cells once again sensitive to Docetaxel and Enzalutamide, with substantial loss of tumorigenic NE-like features (Figures 3, 6 and 7) . These observations lend further support to the view that androgens and AR demonstrate crucial tumor suppressive effects in the prostate. It is in this context that we propose the concomitant use of the p38 inhibitor, which offers the dual benefit of impeding FOXC2-mediated EMT/CSC attributes, while simultaneously restoring AR-derived protection.
In conclusion, we demonstrate that FOXC2 is an important determinant of PCa stem-cell attributes, dictating the biochemical shift to ADT-and chemo-resistance ( Figure 7i ). We propose a novel and tangible method to target FOXC2 functions in vivo, at least in part, through systemic inhibition of p38 signaling. Targeting FOXC2 curtails prostate tumor cell plasticity, by preventing both EMT, as well as NE trans-differentiation. Our future efforts will be directed to examining the molecular basis of FOXC2 function. We believe this represents a cornerstone to our understanding of the fundamental mechanisms dictating stem-cell function and tumor progression in a significant subpopulation of patients harboring variant forms of PCa (such as NEPC or small-cell prostate carcinomas) that are defined by lack of AR/PSA expression, as well as in metastatic CRPCs that arise following ADT.
MATERIALS AND METHODS
Cell lines
Authenticated LNCaP, DU145 and PC3 cells were procured from American Type Culture Collection (ATCC), Manassas, VA, USA and cultured in RPMI with 10% fetal bovine serum with penicillin/streptomycin. Cells overexpressing EMT transcription factors and short hairpin RNA (shRNA) were also cultured in the same media. HEK293T cells were cultured in DMEM with 10% fetal bovine serum and penicillin/streptomycin. All cell lines used for this study were recently confirmed negative for mycoplasma contamination. TGFβ1, LY364947 and SB203580 were used at a final concentration of 5 ng/ml, 1 μM and 5 μM, respectively.
Inhibitor experiments-cell culture
For assessing the effect of inhibition of p38MAPK signaling, cells were treated for 7 days with 5 μM SB203580 45 (EMD-Millipore, Billerica, MA, USA) dissolved in water. For assessing the combined effect of p38MAPK inhibition and the AR antagonist Enzalutamide 27, 46 (SelleckChem, Houston, TX, USA) or the chemotherapeutic Docetaxel 28 (LC Laboratories, Woburn, MA, USA), cells were co-treated with SB203580 and either Enzalutamide/ Docetaxel for 7 days. It is important to note that the concentration of SB203580 used to treat PCa cells in our experiments, results in selective inhibition of p38MAPK signaling, as also suggested in the study by Davies et al. 45 We did not observe any appreciable changes in the phosphorylation of Akt1, another potential target (data not shown).
Vectors
The use of the pCS-PSAP-EGFP-DsRed vector has been described previously. 15 pQXIP-Zeb1 was provided by Dr Harikrishna Nakshatri (Indiana University, Indianapolis, IN, USA), and pBabePuro-Snail, pBabePuro-FOXC2 and pMIG-FOXC2 by Dr Robert Weinberg (Whitehead Institute, MIT, Cambridge, MA, USA). S367E-FOXC2 and S367A-FOXC2 mutant constructs were generated by site-directed mutagenesis and subcloned into the retroviral vector MSCV-IRES-GFP. The pLKO1 lentiviral vector with shFOXC2 is previously described. 16 The pGIPZ lentiviral vectors with shSnail and shZeb1 were procured from MD Anderson shRNA Core Facility, Houston, TX, USA. Two independent shRNA sequences targeting different regions of FOXC2 5′ untranslated region were used for FOXC2 knockdown, with similar results (data shown are representative from one of them). Similarly, for shSnail and shZeb1 as well. shRNA targeting firefly luciferase (shFF3) was used as a control. Sequence details are provided in Table 1 .
Isolation of CTCs
Immediately after sacrificing the mice,~100 μl blood was isolated via venipuncture in EDTA-treated collection tubes and stored on ice. Within 30 min, the blood was spun down at 1200 r.p.m. for 5 min, and the pellet resuspended in 1 ml ACK-lysing buffer (Life Tech) and further incubated for 3-5 min. Cells were washed once with PBS, resuspended in RPMI with 10% fetal bovine serum and pen/strep, and cultured on 10-cm tissue culture dishes. RFP-positive colonies (originating from the labeled DU145 cells injected into mice) were counted after 3-4 days in culture and quantified.
Immunoblotting, immunofluorescence, RT-PCR, wound healing and tumorsphere assays Immunoblotting, immunofluorescence, RT-PCR, wound healing and tumorsphere assays were performed as previously described. 17, 47 Antibody and primer details are provided in Tables 2 and 3 , respectively. Cell viability (MTS) was assessed using the CellTiter96 Aqueous One-Solution Cell Proliferation Assay kit (Promega, Fitchburg, WI, USA).
Immunohistochemistry
Human prostate tumor tissue samples representing benign prostatic hyperplasia, prostatic intraepithelial neoplasia, advanced Gleason Grade 7 and NEPC were obtained from Drs Nupam and Kiran Mahajan. Pathological evaluation was performed by two independent pathologists who agreed on the IHC scoring and the positive pattern expression of the markers. The IHC scoring per se was performed in a 'blinded' manner (wherein the scorers did not have access to disease classification/group allocation information) using the H-score system, including intensity (from 0 to 3+) and percentage of positive cells (from 0 to 100%), with a final scoring ranging from 0 to 300.
Flow cytometry
Fluorescence-activated cell sorting for PSA Hi & PSA -/lo cells and CD44 Hi & CD24 Lo cells was performed as described previously 15, 17 using BD Influx sorter (San Jose, CA, USA).
Animal experiments
Approximately 4-week-old male NOD.CB17-Prkdcscid/J mice were purchased from the Jackson Laboratory (Bar Harbor, MI, USA). All animal procedures were verified and approved by the Institutional Animal care and Use Committee of UTMDACC. To study primary prostate tumor formation, 2 × 10 6 RFP-luciferase-labeled DU145 cells were injected s.c. on both the flanks of 6-week-old male NOD/SCID mice. Once palpable tumors were discernable, tumor-bearing mice were randomly segregated into four groups, and drug treatment was initiated every 24 h for 5 days per week. SB203580 (0.2 μmol in 100 μl per~20 g mouse), Enzalutamide (10 mg/kg) or a combination of both drugs (or vehicle) were administered s.c., and tumor growth was assessed as described previously. 17 Investigators were blinded to the group allocation while assessing experimental outcomes. At the end of the treatment period, tumors were excised, average diameter calculated using calipers and tumor weight noted. Tumors were then processed for RNA isolation and/or fixed in formalin, paraffin-embedded, sectioned and stained with hematoxylin/eosin and pATF2, AR and FOXC2 antibodies.
Statistical analyses
Unless otherwise stated, all samples were assayed in triplicate. All in vitro experiments were repeated at least three independent times, and all (1) 5′-ACTTCTTGACATCTGAGTG -3′ Snail (2) 5′-TGTGGAGCAGGGACATTCG -3′
Abbreviation: shRNA, short hairpin RNA. 
animal experiments included at least 5 mice per group in each study. Unless otherwise indicated, data are represented as mean ± s.e.m., and significance was calculated using Student's unpaired two-tailed t-test.
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